Cargando…

Role of FNA and Core Biopsy of Primary and Metastatic Liver Disease

Objective. To examine our experience with cytology and histology biopsy of the liver and to define methods for improvement of diagnosis of primary liver tumors. Methods. This include retrospective study of 189 biopsies of 185 liver masses for cytological or histological analysis. Patients were subdi...

Descripción completa

Detalles Bibliográficos
Autores principales: McGahan, John P., Bishop, John, Webb, John, Howell, Lydia, Torok, Natalie, Lamba, Ramit, Corwin, Michael T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3857922/
https://www.ncbi.nlm.nih.gov/pubmed/24369506
http://dx.doi.org/10.1155/2013/174103
_version_ 1782295220003536896
author McGahan, John P.
Bishop, John
Webb, John
Howell, Lydia
Torok, Natalie
Lamba, Ramit
Corwin, Michael T.
author_facet McGahan, John P.
Bishop, John
Webb, John
Howell, Lydia
Torok, Natalie
Lamba, Ramit
Corwin, Michael T.
author_sort McGahan, John P.
collection PubMed
description Objective. To examine our experience with cytology and histology biopsy of the liver and to define methods for improvement of diagnosis of primary liver tumors. Methods. This include retrospective study of 189 biopsies of 185 liver masses for cytological or histological analysis. Patients were subdivided into two groups. Group 1 consisted of 124 suspected metastasis. Group 2 consisted of 61 suspected primary neoplasms. Biopsies were considered positive or equivocal. In equivocal cases, special stains were performed. In Group 2, cases were classified by contrast CT or MRI as to (I) classic HCC, (II) infiltrated HCC, or (Ill) equivocal. Results. Definitive diagnosis was obtained in 117/124 masses (94%) in Group 1, 48/61 masses (79%) in Group 2, and (Ill) equivocal 13 cases in Group II. In two equivocal cases in which special stains were performed, they were reclassified as HCC. In 8/13 cases, CT findings were consistent with HCC. Conclusion. Liver biopsies are useful in obtaining a definitive diagnosis of suspected metastatic liver disease. Biopsy results are less reliable in patients with suspected primary liver tumors. In these situations, strategies can include basing treatment on imaging criteria or use of newer special pathological stains. Advances in Knowledge. Use of newer special immunological stains improves accuracy in definitive diagnosis of primary liver tumors.
format Online
Article
Text
id pubmed-3857922
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-38579222013-12-25 Role of FNA and Core Biopsy of Primary and Metastatic Liver Disease McGahan, John P. Bishop, John Webb, John Howell, Lydia Torok, Natalie Lamba, Ramit Corwin, Michael T. Int J Hepatol Clinical Study Objective. To examine our experience with cytology and histology biopsy of the liver and to define methods for improvement of diagnosis of primary liver tumors. Methods. This include retrospective study of 189 biopsies of 185 liver masses for cytological or histological analysis. Patients were subdivided into two groups. Group 1 consisted of 124 suspected metastasis. Group 2 consisted of 61 suspected primary neoplasms. Biopsies were considered positive or equivocal. In equivocal cases, special stains were performed. In Group 2, cases were classified by contrast CT or MRI as to (I) classic HCC, (II) infiltrated HCC, or (Ill) equivocal. Results. Definitive diagnosis was obtained in 117/124 masses (94%) in Group 1, 48/61 masses (79%) in Group 2, and (Ill) equivocal 13 cases in Group II. In two equivocal cases in which special stains were performed, they were reclassified as HCC. In 8/13 cases, CT findings were consistent with HCC. Conclusion. Liver biopsies are useful in obtaining a definitive diagnosis of suspected metastatic liver disease. Biopsy results are less reliable in patients with suspected primary liver tumors. In these situations, strategies can include basing treatment on imaging criteria or use of newer special pathological stains. Advances in Knowledge. Use of newer special immunological stains improves accuracy in definitive diagnosis of primary liver tumors. Hindawi Publishing Corporation 2013 2013-11-21 /pmc/articles/PMC3857922/ /pubmed/24369506 http://dx.doi.org/10.1155/2013/174103 Text en Copyright © 2013 John P. McGahan et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
McGahan, John P.
Bishop, John
Webb, John
Howell, Lydia
Torok, Natalie
Lamba, Ramit
Corwin, Michael T.
Role of FNA and Core Biopsy of Primary and Metastatic Liver Disease
title Role of FNA and Core Biopsy of Primary and Metastatic Liver Disease
title_full Role of FNA and Core Biopsy of Primary and Metastatic Liver Disease
title_fullStr Role of FNA and Core Biopsy of Primary and Metastatic Liver Disease
title_full_unstemmed Role of FNA and Core Biopsy of Primary and Metastatic Liver Disease
title_short Role of FNA and Core Biopsy of Primary and Metastatic Liver Disease
title_sort role of fna and core biopsy of primary and metastatic liver disease
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3857922/
https://www.ncbi.nlm.nih.gov/pubmed/24369506
http://dx.doi.org/10.1155/2013/174103
work_keys_str_mv AT mcgahanjohnp roleoffnaandcorebiopsyofprimaryandmetastaticliverdisease
AT bishopjohn roleoffnaandcorebiopsyofprimaryandmetastaticliverdisease
AT webbjohn roleoffnaandcorebiopsyofprimaryandmetastaticliverdisease
AT howelllydia roleoffnaandcorebiopsyofprimaryandmetastaticliverdisease
AT toroknatalie roleoffnaandcorebiopsyofprimaryandmetastaticliverdisease
AT lambaramit roleoffnaandcorebiopsyofprimaryandmetastaticliverdisease
AT corwinmichaelt roleoffnaandcorebiopsyofprimaryandmetastaticliverdisease